Shares of Uniqure NV (NASDAQ:QURE) have been assigned an average rating of “Buy” from the eleven research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $21.50.
A number of equities research analysts have recently commented on QURE shares. Evercore ISI started coverage on shares of Uniqure in a report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price target for the company. Leerink Swann lifted their price target on shares of Uniqure from $19.00 to $26.00 in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Oppenheimer reiterated a “hold” rating on shares of Uniqure in a report on Friday, November 24th. Finally, HC Wainwright started coverage on shares of Uniqure in a report on Friday, December 1st. They set a “buy” rating and a $28.00 price target for the company.
In related news, Director David Schaffer sold 2,878 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $18.53, for a total value of $53,329.34. Following the completion of the sale, the director now directly owns 15,314 shares in the company, valued at $283,768.42. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Deventer Sander Van sold 5,985 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $18.53, for a total transaction of $110,902.05. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,510 shares of company stock valued at $815,776. 0.73% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. grew its holdings in Uniqure by 660.1% in the fourth quarter. Macquarie Group Ltd. now owns 532,049 shares of the biotechnology company’s stock valued at $10,423,000 after purchasing an additional 462,049 shares during the period. Perceptive Advisors LLC grew its holdings in Uniqure by 0.8% in the fourth quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock valued at $20,529,000 after purchasing an additional 7,831 shares during the period. Two Sigma Investments LP purchased a new stake in Uniqure in the fourth quarter valued at approximately $2,721,000. Two Sigma Advisers LP purchased a new stake in Uniqure in the fourth quarter valued at approximately $476,000. Finally, Ellington Management Group LLC purchased a new stake in Uniqure in the fourth quarter valued at approximately $237,000. Hedge funds and other institutional investors own 44.05% of the company’s stock.
Shares of Uniqure (NASDAQ:QURE) traded up $0.27 during midday trading on Wednesday, hitting $25.92. 230,263 shares of the stock were exchanged, compared to its average volume of 393,862. The stock has a market capitalization of $797.11, a P/E ratio of -10.00 and a beta of 0.09. Uniqure has a 1-year low of $4.72 and a 1-year high of $27.19. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/03/14/uniqure-nv-qure-given-consensus-rating-of-buy-by-analysts.html.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.